Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma.

Chaiteerakij R, Juran BD, Aboelsoud MM, Harmsen WS, Moser CD, Giama NH, Allotey LK, Mettler TA, Baichoo E, Zhang X, Therneau TM, Lazaridis KN, Roberts LR.

Cancer Med. 2015 Oct;4(10):1599-602. doi: 10.1002/cam4.501. Epub 2015 Aug 15.

2.

Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms.

Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, Lie BA.

Hepatology. 2008 Jan;47(1):90-6.

PMID:
18023027
3.

Elevated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 in primary sclerosing cholangitis: ιmplications for cholangiocarcinogenesis.

Ishii Y, Sasaki T, Serikawa M, Minami T, Okazaki A, Yukutake M, Ishigaki T, Kosaka K, Mouri T, Yoshimi S, Shimizu A, Tsuboi T, Chayama K.

Int J Oncol. 2013 Oct;43(4):1073-9. doi: 10.3892/ijo.2013.2038. Epub 2013 Jul 24.

PMID:
23900502
4.

Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymorphisms.

Songserm N, Promthet S, Sithithaworn P, Pientong C, Ekalaksananan T, Chopjitt P, Parkin DM.

Cancer Epidemiol. 2012 Apr;36(2):e89-94. doi: 10.1016/j.canep.2011.11.007. Epub 2011 Dec 19.

PMID:
22189445
5.

Association of NRF2 polymorphism with cholangiocarcinoma prognosis in Thai patients.

Khunluck T, Kukongviriyapan V, Puapairoj A, Khuntikeo N, Senggunprai L, Zeekpudsa P, Prawan A.

Asian Pac J Cancer Prev. 2014;15(1):299-304.

6.

A common variant in the precursor miR-146a sequence does not predispose to cholangiocarcinoma in a large European cohort.

Mihalache F, Hoblinger A, Acalovschi M, Sauerbruch T, Lammert F, Zimmer V.

Hepatobiliary Pancreat Dis Int. 2012 Aug 15;11(4):412-7.

PMID:
22893469
7.

Macrophage stimulating protein variation enhances the risk of sporadic extrahepatic cholangiocarcinoma.

Krawczyk M, Höblinger A, Mihalache F, Grünhage F, Acalovschi M, Lammert F, Zimmer V.

Dig Liver Dis. 2013 Jul;45(7):612-5. doi: 10.1016/j.dld.2012.12.017. Epub 2013 Feb 16.

PMID:
23422030
8.

Prognostic assessment of three single-nucleotide polymorphisms (GNB3 825C>T, BCL2-938C>A, MCL1-386C>G) in extrahepatic cholangiocarcinoma.

Fingas CD, Katsounas A, Kahraman A, Siffert W, Jochum C, Gerken G, Nückel H, Canbay A.

Cancer Invest. 2010 Jun;28(5):472-8. doi: 10.3109/07357900903095714.

PMID:
19968497
9.

Catalytically impaired hMYH and NEIL1 mutant proteins identified in patients with primary sclerosing cholangitis and cholangiocarcinoma.

Forsbring M, Vik ES, Dalhus B, Karlsen TH, Bergquist A, Schrumpf E, Bjørås M, Boberg KM, Alseth I.

Carcinogenesis. 2009 Jul;30(7):1147-54. doi: 10.1093/carcin/bgp118. Epub 2009 May 14.

10.

Gene-environment interaction involved in cholangiocarcinoma in the Thai population: polymorphisms of DNA repair genes, smoking and use of alcohol.

Songserm N, Promthet S, Pientong C, Ekalaksananan T, Chopjitt P, Wiangnon S.

BMJ Open. 2014 Oct 21;4(10):e005447. doi: 10.1136/bmjopen-2014-005447.

11.

Molecular mechanism of cholangiocarcinoma carcinogenesis.

Maemura K, Natsugoe S, Takao S.

J Hepatobiliary Pancreat Sci. 2014 Oct;21(10):754-60. doi: 10.1002/jhbp.126. Epub 2014 Jun 3. Review.

PMID:
24895231
12.

Association of Endoscopic Sphincterotomy or Papillary Balloon Dilatation and Biliary Cancer: A Population-Based Cohort Study.

Peng YC, Lin CL, Hsu WY, Chow WK, Lee SW, Yeh HZ, Chang CS, Kao CH.

Medicine (Baltimore). 2015 Jun;94(23):e926. doi: 10.1097/MD.0000000000000926.

13.

Aspirin use and the risk of cholangiocarcinoma.

Choi J, Ghoz HM, Peeraphatdit T, Baichoo E, Addissie BD, Harmsen WS, Therneau TM, Olson JE, Chaiteerakij R, Roberts LR.

Hepatology. 2016 Sep;64(3):785-96. doi: 10.1002/hep.28529. Epub 2016 Apr 26.

14.

Association between praziquantel treatment and cholangiocarcinoma: a hospital-based matched case-control study.

Kamsa-Ard S, Luvira V, Pugkhem A, Luvira V, Thinkhamrop B, Suwanrungruang K, Bhudhisawasdi V.

BMC Cancer. 2015 Oct 24;15:776. doi: 10.1186/s12885-015-1788-6.

15.

Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis.

Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD.

Am J Gastroenterol. 2004 Mar;99(3):523-6.

PMID:
15056096
16.

Global identification and characterization of lncRNAs that control inflammation in malignant cholangiocytes.

Han BW, Ye H, Wei PP, He B, Han C, Chen ZH, Chen YQ, Wang WT.

BMC Genomics. 2018 Oct 11;19(1):735. doi: 10.1186/s12864-018-5133-8.

17.

Primary sclerosing cholangitis and cholangiocarcinoma.

Lazaridis KN, Gores GJ.

Semin Liver Dis. 2006 Feb;26(1):42-51. Review.

PMID:
16496232
18.

Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.

Lewis JT, Talwalkar JA, Rosen CB, Smyrk TC, Abraham SC.

Am J Surg Pathol. 2010 Jan;34(1):27-34. doi: 10.1097/PAS.0b013e3181bc96f9.

PMID:
19898228
19.

Cholangiocarcinoma: risk factors and clinical presentation.

Gatto M, Alvaro D.

Eur Rev Med Pharmacol Sci. 2010 Apr;14(4):363-7. Review.

PMID:
20496549
20.

Statins are associated with a reduced risk of cholangiocarcinoma: a population-based case-control study.

Peng YC, Lin CL, Hsu WY, Chang CS, Yeh HZ, Tung CF, Wu YL, Sung FC, Kao CH.

Br J Clin Pharmacol. 2015 Oct;80(4):755-61. doi: 10.1111/bcp.12641. Epub 2015 May 26.

Supplemental Content

Support Center